02156nas a2200325   4500000000100000000000100001008004100002260001500043653002000058653001800078653002700096100001400123700001800137700001700155700002000172700001400192700001700206700001600223700001900239700001700258700001900275700001500294700001900309245014400328856005500472300001000527490000700537520127200544022001401816       2025                            d  c2025-11-2510aImmunochemistry10aLab-on-a-chip10atranslational research1 aGaeun Lee1 aYu-Gyeong Lee1 aHwa Seon Koo1 aSun-Young Hwang1 aDanbi Lee1 aJungseub Lee1 aWon Jong Yu1 aYoon Young Kim1 aSeung-Yup Ku1 aJong-Chan Park1 aJungho Ahn1 aYoun-Jung Kang00aMicroengineered patient-derived endometrium-on-a-chip for the evaluation of endometrial receptivity and personalised translational medicine  uhttps://www.nature.com/articles/s41467-025-65406-7  a104390 v163 aEndometrial receptivity is a critical determinant of embryo implantation and early pregnancy success; however, current methods for assessing endometrial receptivity remain poorly validated and insufficiently reliable for clinical application. Here, we establish a patient-derived vascularised endometrium-on-a-chip (EoC), successfully replicating the dynamic microenvironment and both temporal and spatial architecture of native endometrial tissue. Using our EoC, we develop a clinically relevant endometrial receptivity scoring system, ERS2, which integrates molecular profiling of established receptivity markers with quantitative analyses of angiogenesis. The ERS2 enables personalised assessment of endometrial health and implantation potential, addressing inter-patient variability often overlooked by conventional techniques. By leveraging our EoC to therapeutic monitoring, we observe progressive restoration of the endometrial microenvironment following platelet-rich-plasma treatments, highlighting the translational utility of our model. This study represents the innovative application of a patient-derived EoC and scoring system to assess receptivity, offering personalised infertility management and advancing targeted therapies in reproductive medicine.  a2041-1723